Liquidia price to sales ratio LQDA

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: 8.5×
8-year median: 30.0×
Against its 8-year history: 3rd; percentile: 0 is its lowest day, 100 its highest
8-year range: 5.4× to 129×
Peer median: 3.5×

Liquidia's price to sales ratio is 8.5× as of Oct 23, 2026.

That is below its 8-year median of 30.0×, lower than on 97% of days in the last 8 years.

Over that time it ranged from 5.4× in Oct 2026 to 129× in Sep 2025.

The median for 10 large drugmakers of a similar size is 3.5×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	8.5×	5.4×	54.1×
2025	43.2×	32.8×	129×
2024	62.7×	43.1×	73.0×
2023	42.6×	22.2×	42.6×
2022	29.8×	18.9×	35.0×
2021	24.4×	18.7×	40.9×
2020	21.9×	8.6×	38.3×
2019	10.7×	6.7×	115×

Against its peers

Companies in Drug Manufacturers - General nearest Liquidia's size, closest first, today.

Company	Price to sales ratio
LQDALiquidia	8.5×
ARQTArcutis Biotherapeutics	8.5×
OGNOrganon	0.6×
INDVIndivior Pharmaceuticals	3.1×
NRIXNurix Therapeutics	3.9×
KNSAKiniksa Pharmaceuticals International	7.1×
LGNDLigand Pharmaceuticals	20.8×
PBHPrestige Consumer Healthcare	2.0×
AMRXAmneal Pharmaceuticals	2.1×
HRMYHarmony Biosciences	2.2×
ALKSAlkermes plc.	4.4×
Peer median	3.5×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Liquidia

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.